Topic
Our mission is to ensure that all patients in Switzerland receive the best possible medicines and therapies for their needs as quickly as possible as part of their basic health insurance cover. For this to happen, medicinal products need to be authorised promptly by Swissmedic, basic health insurance needs to cover products from day 1 of authorisation, and there need to be sustainable models to reward innovations. We ensure that these medicinal products and therapies are of the highest possible quality. And we play our part in making sure that the cost of these therapies remains commensurate with the benefit they offer for patients, society and the economy.
3 questions to Thorsten Hein - Member of theInterpharma Board and Country Division Head Pharmaceuticals Bayer Switzerland
3 questions to Graham Dorey - Member Interpharma Board and General Manager Switzerland, Biogen
3 questions to Max Pahlow - Member Interpharma Board and Managing Director, Janssen Switzerland
Pharma Market in Switzerland
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2022
Introducing Interpharma
More about the tasks and overriding aims of Interpharma
Contact us
Latest information and media contacts for media representatives